Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with advanced unresectable pancreatic carcinoma. Clinical data from patients diagnosed with pancreatic adenocarcinoma will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of Medical Oncology of the University Department of Medicine, Queen Mary Hospital, Hong Kong.

Official Title
-----------------
An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

Conditions
-----------------
Pancreatic Adenocarcinoma

Intervention / Treatment
-----------------
* Drug: Capecitabine
* Drug: Oxaliplatin
* Drug: Irinotecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ≥ 18 years of age, male or female. Histopathologically or cytologically confirmed adenocarcinoma of the pancreas. ECOG performance status 0 to 2. Adequate bone marrow reserve. Absolute neutrophil count > 1x10^9/L. Total bilirubin <3 times the upper limit of the normal range. Life expectancy ≥ 12 weeks. Signed written informed consent form. Exclusion Criteria: Prior malignant disease other than pancreatic cancer. Patients suitable for surgical or locoregional therapies. Patients who have prior anticancer therapy for pancreatic cancer. Patients unable to swallow oral medications. Any evidence of brain metastasis (unless the patient is >6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). Active clinically serious infections (> grade 2 NCI / CTC Adverse Event version 3.0). History of allergy to platinum compounds. Patients who have chronic inflammatory bowel disease and/or bowel obstruction. Patients who have severe bone marrow failure. Patients undergoing renal dialysis. History of HIV infection. Seizure disorder requiring medication (such as steroids or anti-epileptics). Women who are pregnant or breast-feeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Capecitabine<br>* 1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)<br>* Other names: Xeloda;Drug: Oxaliplatin<br>* 70 mg/m2 IV on day 1 of a 2-week cycle<br>Drug: Irinotecan<br>* 130 mg/m2 IV on day 1 of a 2-week cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in extent of disease | Objective response rate | Change from baseline in size approximately every 4 cycles | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CA19.9 reduction |  | Change from baseline every 2 cycles | 
| Progression-free survival |  | From date of start until the date of first documented progression or death from disease-related causes or last follow-up, whichever came first, assessed up to 18 months | 
| Overall survival |  | From date of start until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months |